Weill Cornell GI Oncology Program

04/17/2026

The liver plays a very important role in cancer care due to the body’s anatomy and its role in processing nutrients and medications. Treatments for and metastatic disease are rapidly evolving through precision surgery, targeted therapies and new “no-cut” technologies that can destroy tumors without removing them. These innovations are helping doctors target tumors more effectively, reducing recovery time, and increasing treatment access for more patients than ever before, including patients with liver metastases. Learn more:

Liver cancer care is evolving quickly with new tools and technologies that are helping to expand what treatment is possible for patients with both primary liver tumors and other forms of cancer that have spread to the liver, also known as metastatic disease.

04/14/2026

Mismatch repair-deficient is a form of caused by mutations in some of the genes involved in correcting mistakes made when DNA is copied in a cell. It’s important to understand how this genetic abnormality is actually opening the door to new and more effective treatment options, like immunotherapy, for this subtype. An in-depth look at the why behind these advances and what patients and loved ones should know:

Mismatch repair-deficient (dMMR) colon cancer, also known as microsatellite instability-high (MSI-H), is a biologically distinct form of colorectal cancer caused by mutations in some of the genes that are involved in correcting mistakes made when DNA is copied in a cell. This type of colon cancer is...

04/08/2026

Innovative liver-directed therapies continue to expand treatment options for and liver metastases. Transplantation, surgery, histotripsy and ablation are giving patients more options than ever before. In this episode of CancerCast, Dr. Manish Shah is joined by Dr. Juan Rocca, Surgical Director of the Weill Cornell Liver Cancer Program, to break down the liver’s role in cancer care and the latest treatment updates. Listen: https://bit.ly/4jDZGo2

04/02/2026

In another Targeted Oncology interview, Dr. Rutika Mehta talks about gaps that should be addressed before circulating tumor DNA (ctDNA) testing is more widely integrated into standard of care for patients:

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials.

03/31/2026

March is . Did you know that mismatch repair-deficient has unique traits that change how it responds to treatment? Dr. Manish Shah spoke with two experts on the CancerCast podcast about how immunotherapy and genetic testing for are changing outcomes for people with this form of and who are most at risk for developing it. Listen to the episode: https://bit.ly/4hyecwH

03/30/2026

Hosted by Dr. Manish Shah, Chief of the Soid Tumor Oncology Program Weill Cornell Medicine, the CancerCast podcast offers conversations designed to support, inform, and empower people living with cancer, their loved ones, and caregivers. Each episode features in depth discussions with leading experts who help break down complex advances in cancer diagnosis, treatment, and research. Recent topics explore cutting edge technologies and breakthroughs across many types of cancer. Tune in and subscribe to stay informed about the innovations and insights shaping the future of cancer care.

Listen to the episodes on Apple Podcasts (https://bit.ly/40IugnI), Spotify (https://bit.ly/47r9c94), YouTube (https://bit.ly/4nRMEon), or at weillcornell.org/cancercast.

03/30/2026

From : Dr. Rutika Mehta talked with Oncology Learning Network about reintroducing after previously stopping it for patients with /

Rutika Mehta, MD, discusses whether immunotherapy rechallenge should be considered for patients with esophageal and gastric cancers.

03/26/2026

In this interview with Targeted Oncology, Dr. Rutika Mehta outlines what clinicians should know when deciding to use circulating tumor DNA (ctDNA) or minimal residual disease (MRD) testing to manage patients:

Learn how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising ctDNA means before scans.

03/19/2026

ICYMI: Dr. Rutika Mehta spoke with Targeted Oncology about the role of circulating tumor DNA (ctDNA) to improve early detection of recurrence in .

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

03/12/2026

Dr. Rutika Mehta spoke with Targeted Oncology about a study looking at using circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing in to help inform prognosis, treatment duration, toxicity, and potential treatment breaks:

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

02/26/2026

12/23/2025

Dr. Rutika Mehta moderated a program to discuss results from a phase 3 evaluating a combination treatment regimen recently approved by the U.S. Food and Drug Administration for :

A panel of experts gathered to discuss results from the MATTERHORN trial assessing durvalumab plus FLOT in gastric/GEJ cancer.